These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

911 related items for PubMed ID: 33971168

  • 1. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG, Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium).
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I.
    Cochrane Database Syst Rev; 2020 Dec 08; 12(12):CD013432. PubMed ID: 33295032
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Anti-IL-5 therapies for asthma.
    Farne HA, Wilson A, Milan S, Banchoff E, Yang F, Powell CV.
    Cochrane Database Syst Rev; 2022 Jul 12; 7(7):CD010834. PubMed ID: 35838542
    [Abstract] [Full Text] [Related]

  • 7. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
    Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID.
    Lancet Respir Med; 2021 Oct 12; 9(10):1165-1173. PubMed ID: 34181876
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M.
    Clin Ther; 2019 Oct 12; 41(10):2041-2056.e5. PubMed ID: 31447130
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.
    Lancet Respir Med; 2017 May 12; 5(5):390-400. PubMed ID: 28395936
    [Abstract] [Full Text] [Related]

  • 13. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG, ANDHI study investigators.
    Lancet Respir Med; 2021 Mar 12; 9(3):260-274. PubMed ID: 33357499
    [Abstract] [Full Text] [Related]

  • 14. Mepolizumab and exacerbations of refractory eosinophilic asthma.
    Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.
    N Engl J Med; 2009 Mar 05; 360(10):973-84. PubMed ID: 19264686
    [Abstract] [Full Text] [Related]

  • 15. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE, Bleecker ER, Panettieri RA, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R.
    Lancet Respir Med; 2014 Nov 05; 2(11):891-901. PubMed ID: 25208464
    [Abstract] [Full Text] [Related]

  • 16. Exhaled nitric oxide levels to guide treatment for children with asthma.
    Petsky HL, Kew KM, Chang AB.
    Cochrane Database Syst Rev; 2016 Nov 09; 11(11):CD011439. PubMed ID: 27825189
    [Abstract] [Full Text] [Related]

  • 17. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
    Caminati M, Cegolon L, Vianello A, Chieco Bianchi F, Festi G, Marchi MR, Micheletto C, Mazza F, Tognella S, Senna G.
    Expert Rev Respir Med; 2019 Dec 09; 13(12):1205-1212. PubMed ID: 31592700
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils).
    Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB.
    Thorax; 2012 Mar 09; 67(3):199-208. PubMed ID: 20937641
    [Abstract] [Full Text] [Related]

  • 20. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
    Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S.
    Respir Med; 2019 Nov 09; 159():105806. PubMed ID: 31751853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.